Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Protalix’s proprietary technology is based on its plant cell culture and bioreactor system which provides an effective and scaleable cell system for industrial production of recombinant biophamaceuticals. Protalix has recently announced that it has completed Phase I clinical studies for its enzyme therapy for Gaucher disease, nder and FDA Investigational New Drug study. Protalix intends to pursue advanced clincal studies for its enzyme therapy for Gaucher disease and advance additional recombinant biopharmaceutical drug development programs. ( www.protalix.com )
Protalix Biotherapeutics Ltd.
1428 Brickell Avenue Suite 105
Miami, Florida 33131
USA
Tel: (305) 446-8661